Inhibitors of striatin-interacting proteins and their use in the preparation of anti-tumor drugs

By inhibiting the expression of STRIP and binding to oncolytic vaccinia virus, the replication ability of viruses in tumor cells is significantly improved, the problem of tumor cells' replication and antiviral ability of viruses is solved, and new anti-tumor drug development pathways are provided.

CN109453392BActive Publication Date: 2024-11-26HANGZHOU GONGCHU BIOTECH CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN201811215763.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2018-10-18
Publication Date
2024-11-26
Estimated Expiration
2038-10-18

AI Technical Summary

Technical Problem

The replication and anti-tumor effects of existing oncolytic viruses in tumor cells are affected by the regulation of titin interacting protein (STRIP) in tumor cells, and the specific regulatory relationship with oncolytic vaccinia virus is not clear, which affects the anti-tumor drugs. Development.

Method used

By inhibiting the expression of STRIP1 and STRIP2, siRNA or shRNA interference technology is used to reduce the antiviral ability of tumor cells, and combined with oncolytic vaccinia virus, STRIP shRNA recombinant vector is constructed to improve the replication ability of the virus in tumor cells.

Benefits of technology

It significantly reduces the antiviral ability and antiviral response level of tumor cells, improves the replication level of oncolytic vaccinia virus in tumor cells, thereby enhancing the anti-tumor effect and providing a new way for the research and development of anti-tumor drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN109453392B_ABST
    Figure CN109453392B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of biomedical engineering technology, and provides the use of a striae-interacting protein (STRIP) inhibitor in the preparation of an anti-tumor drug, a striae-interacting protein inhibitor recombinant vector and its use in the preparation of an anti-tumor drug, and an anti-tumor drug composition with a striae-interacting protein inhibitor or a striae-interacting protein inhibitor recombinant vector as an active component. The present invention can be used to prepare an anti-tumor viral drug by inhibiting STRIP, especially by recombining it with vaccinia virus into a recombinant vector, which can combine the advantages of STRIP inhibitors and vaccinia virus, provide a new target for viral treatment of tumors, and has broad clinical application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of striatin interacting protein (STRIP) as a target in the preparation of anti-tumor drugs, and carriers and drugs containing the same. Background Art

[0002] Oncolytic viruses refer to therapeutically valuable viruses that can selectively infect and damage tumor tissues. Oncolytic viruses have a long history. So far, oncolytic viruses belonging to 10 virus families have entered clinical trials, including adenovirus, Coxsackie virus, herpes simplex virus (HSV), measles virus, Newcastle disease virus, parvovirus, poliovirus, reovirus, vaccinia virus and vesicular stomatitis virus. Currently, the herpes virus T-VEC has been approved by the FDA to treat melanoma. Overall, oncolytic viruses have shown considerable safety and efficacy in clinical trials.

[0003] Vaccinia virus is a large double-stranded DNA virus in the poxvirus family. Compared with other oncolytic viruses, it has the following advantages: (1) It is unique among DNA viruses because it replicates only in the cytoplasm to minimize the risk of integration into the host genome; (2) Vaccinia virus was first made into a vaccine to fight smallpox virus, and its safety is highly guaranteed; (3) Vaccinia virus has a large cloning capacity, which can allow the insertion of larger gene fragments; and (4) The virus has a strong replication ability.

[0004] Oncolytic vaccinia viruses have shown anti-tumor efficacy. Most of the common oncolytic vaccinia viruses currently have been attenuated, including strains with thymidine kinase TK gene deletion or TK / vaccinia virus growth factor gene double deletion. The deletion of the TK gene makes the replication of vaccinia virus more dependent on the level of TK in the cell, and cancer cells often have higher levels of TK than normal cells; in addition, the replication of vaccinia virus also depends on the drive of the epidermal growth factor receptor EGFR / Ras pathway, making it highly selective for cancer cells. Oncolytic vaccinia virus has shown the ability to target and aggregate to cancer tissues in both experimental animals and humans, and has therefore become an ideal viral vector for cancer treatment.

[0005] Striatin interacting protein (STRIP) is a component of the striatin interacting phosphatases and kinases (STRIPAK) complex (Goudreault, M., LMD'Ambrosio, et al. 2009. A PP2A phosphatase high density interaction network identifies a novel striatin-interacting phosphatase and kinase complex linked to the cerebral cavernous malformation 3 (CCM3) protein. Mol Cell Proteomics 8(1): 157-171.), including STRIP1 (GenBank No. NM_033088.3) and STRIP2 (GenBank No. NM_020704.2), also known as FAM40A and FAM40B. Previous studies have shown that Drosophila STRIP participates in negatively regulating CLOCK protein dephosphorylation, thereby participating in regulating circadian rhythms (Andreazza, S., S. Bouleau, et al. 2015. Daytime CLOCK Dephosphorylation Is Controlled by STRIPAK Complexes in Drosophila. Cell Rep 11(8): 1266-1279.). STRIP1 is an important factor in regulating the normal migration of mouse embryonic mesoderm (Bazzi, H., E. Soroka, et al. 2017. STRIP1, a core component of STRIPAK complexes, is essential for normal mesoderm migration in the mouse embryo. Proc Natl Acad Sci USA 114(51): E10928-E10936.).STRIP2 performs key functions in the differentiation of mouse embryonic stem cells (Sabour, D., SP Srinivasan, et al. 2017. STRIP2 Is Indispensable for the Onset of Embryonic Stem Cell Differentiation. Mol Ther Methods Clin Dev 5: 116-129.). In addition, studies on breast cancer mouse models have shown that inhibiting the level of STRIP1 can increase the metastasis of breast cancer cells in mice, while increasing the level of STRIP1 can inhibit the metastasis of breast cancer cells. On the contrary, inhibiting the level of STRIP2 inhibits the metastasis of breast cancer cells in mice (Madsen, CD, S. Hooper, et al. 2015. STRIPAK components determine mode of cancer cell migration and metastasis. Nat Cell Biol 17 (1): 68-80.).

[0006] It can be seen that STRIP plays an important role in the cell differentiation of both lower and higher organisms, and is also related to the metastasis of breast cancer cells, but there are no reports on whether there is a regulatory relationship between STRIP and the growth and inhibition of other tumors. In addition, there are no reports on whether the oncolytic vaccinia virus is used as a vector and combined with STRIP, whether there is only a simple vector expression relationship between the two, or whether STRIP can also regulate the replication of oncolytic vaccinia virus in tumor cells.

[0007] This study regulated the replication level of oncolytic vaccinia virus in tumor cells by inhibiting STRIP, and significantly improved the tumor-lytic effect of oncolytic vaccinia virus, providing a new technical approach for the development of oncolytic virus anti-tumor drugs. Summary of the invention

[0008] The first purpose of the present invention is to study the relationship between striatum-interacting protein (STRIP) and tumor cells, and provide new uses of striatum-interacting protein (STRIP) inhibitors; another purpose of the present invention is to study the regulatory relationship between STRIP and oncolytic vaccinia virus invading tumor cells, and provide a new technical approach for the research and development of oncolytic virus anti-tumor drugs.

[0009] The present invention has found through research that siRNA interference of STRIP1 and STRIP2 can significantly reduce the transcription levels of antiviral factors Interferon-induced protein with tetratricopeptide repeats1 (IFIT1), DExH-Box Helicase 58 (DHX58) and Interferon-stimulated gene 15 (ISG15) in malignant glioblastoma U87MG cells (such as Figure 1 shown).

[0010] STRIP1 shRNA interference can significantly reduce the expression level of the antiviral factor IFI16 in liver cancer cells SMMC-7721 (such as Figure 2 shown).

[0011] Interference with STRIP1 increased the expression of caspase 3 and caspase 8, indicating that interference with STRIP1 helps to increase the sensitivity of tumor cells to apoptosis induction (see Figure 4 shown).

[0012] It can be seen from this that inhibiting STRIP can significantly reduce the antiviral ability of tumor cells and can be used to prepare anti-tumor viral drugs.

[0013] Therefore, the first aspect of the present invention provides a use of a striatin-interacting protein inhibitor in the preparation of an anti-tumor drug.

[0014] The striatin-interacting protein inhibitor is any substance that can reduce the activity of STRIP, reduce the stability of STRIP, inhibit the expression of STRIP, reduce the effective action time of STRIP, or inhibit the transcription and processing of STRIP, including but not limited to: small interfering molecules that specifically interfere with the expression and processing of STRIP genes, such as shRNA molecules, siRNA molecules, antisense nucleotides, etc.; STRIP antagonists, downregulators, blockers, blocking agents, etc. Small interfering RNA molecules, short hairpin RNAs or antisense nucleotides that specifically interfere with the expression of STRIP genes are preferred, and short hairpin RNAs with simple structures are more preferred.

[0015] The sequence of the short hairpin RNA is shown in the following table:

[0016]

[0017] The coding DNA sequence of the short hairpin RNA is shown in the following table:

[0018]

[0019] The second aspect of the present invention provides a striatin-interacting protein inhibitor recombinant vector and its use in the preparation of anti-tumor drugs.

[0020] The striatin-interacting protein inhibitor recombinant vector comprises an expression vector and a coding DNA sequence of STRIP siRNA, STRIP shRNA or STRIP antisense nucleotide inserted into the expression vector.

[0021] The vectors include viral vectors and non-viral vectors.

[0022] The "viral vector" includes adenovirus, adeno-associated virus, lentivirus, coxsackie virus, herpes simplex virus, measles virus, Newcastle disease virus, parvovirus, poliovirus, reovirus, vaccinia virus and vesicular stomatitis virus, etc. Suitable viral vectors are well known to those of ordinary skill in the art.

[0023] The "non-viral vector" includes liposomes or lipid complexes, cationic polymers, chitosan polymers and nanoparticle vectors, etc. Suitable non-viral vectors are well known to those skilled in the art.

[0024] In addition, the inventors found through research that shRNA interference of STRIP1 significantly inhibited the activation of ISRE transcriptional activity by vaccinia virus, indicating that inhibition of STRIP1 can reduce the response level of tumor cells to vaccinia virus (such as Figure 3 The replication level of oncolytic vaccinia virus oncoVV-STRIP1shRNA in tumor cells was significantly higher than that of control virus (as shown in Figure 5 shown).

[0025] Therefore, the third aspect of the present invention particularly provides an oncolytic vaccinia virus STRIP shRNA recombinant vector and its use in the preparation of anti-tumor drugs.

[0026] Preferably, the vaccinia virus is a vaccinia virus Western Reserve strain, a vaccinia virus Tiantan strain, a vaccinia virus Wyeth strain, a vaccinia virus Copenhagen strain, a vaccinia virus Lister strain or a vaccinia virus NYCBH strain.

[0027] In a fourth aspect of the present invention, an antitumor pharmaceutical composition is provided, which comprises an active component and a medically acceptable excipient, carrier or diluent. The active component comprises a striatin-interacting protein inhibitor or a striatin-interacting protein inhibitor recombinant vector.

[0028] The striatin-interacting protein inhibitor, striatin-interacting protein inhibitor recombinant vector, oncolytic vaccinia virus oncoVV-STRIP1shRNA, etc. of the present invention can inhibit the growth of most tumor cells such as liver cancer, glioma, breast cancer, lung cancer, gastrointestinal carcinoid, prostate cancer, etc.

[0029] The recombinant virus of the present invention and pharmaceutically acceptable excipients together constitute an anti-tumor drug composition, thereby exerting therapeutic effects more stably. These preparations can ensure the conformational integrity of the amino acid core sequence of the bispecific antibody disclosed in the present invention, while protecting the multifunctional groups of the protein to prevent its degradation (including but not limited to aggregation, deamination or oxidation).

[0030] Generally, liquid preparations can be kept stable for at least one year at 2°C-8°C, and freeze-dried preparations can be kept stable for at least six months at 30°C. The preparations can be suspensions, water injections, freeze-dried preparations and other preparations commonly used in the pharmaceutical field.

[0031] When the recombinant virus and its composition in the present invention are administered to animals including humans, the dosage varies depending on the patient's age and weight, disease characteristics and severity, and administration route. The results of animal experiments and various situations can be referred to, and the total dosage cannot exceed a certain range.

[0032] Beneficial protection and effects of the present invention:

[0033] The present invention provides the use of a striae-interacting protein (STRIP) inhibitor in the preparation of an anti-tumor drug. Experiments have confirmed that a STRIP inhibitor can lead to a decrease in the antiviral ability of tumor cells, which is conducive to the massive replication of viruses in tumor cells. In addition, STRIP shRNA interference significantly inhibits the activation of ISRE transcriptional activity by vaccinia virus, indicating that STRIP1 inhibition can reduce the response level of tumor cells to vaccinia virus, and at the same time, the replication level of oncolytic vaccinia virus oncoVV-STRIP1shRNA in tumor cells is significantly higher than that of control virus. Therefore, the present invention can be used to prepare anti-tumor viral drugs for the inhibition of STRIP, especially to reconstitute it with vaccinia virus into a recombinant vector, which can combine the advantages of STRIP inhibitors and vaccinia virus, provide a new target for viral therapy of tumors, and have broad clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1The effect of STRIP1 and STRIP2 siRNA interference on the transcription levels of antiviral factors Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1), DExH-BoxHelicase 58 (DHX58) and Interferon-stimulated gene 15 (ISG15) in malignant glioblastoma U87MG cells.

[0035] Figure 2 The effect of STRIP1 shRNA interference on the expression level of antiviral factor IFI16 in liver cancer cell SMMC-7721.

[0036] Figure 3 The effect of SHRNA interference of STRIP1 on the activation of interferon-stimulated response element ISRE after U87MG cells were infected with vaccinia virus.

[0037] Figure 4 This is the effect of shRNA interference of STRIP1 on the expression levels of caspase 3 and caspase 8 in U87MG cells.

[0038] Figure 5 After STRIP1 shRNA interference in U87MG cells, the growth of transplanted tumors in mice was significantly inhibited.

[0039] Figure 6 This is the pCB-STRIP1shRNA plasmid map.

[0040] Figure 7 Comparison of the replication levels of oncolytic vaccinia viruses oncoVV-STRIP1shRNA#2, oncoVV-STRIP1shRNA#3 and control virus oncoVV in tumor cells SHG44 (A), BEL-7404 (B) and U87MG (C).

[0041] Figure 8 The MTT method was used to detect the growth inhibitory effects of oncolytic vaccinia virus oncoVV-STRIP1shRNA#2 and oncoVV-STRIP1 shRNA#3 on tumor cells MDA-MB-231(A), BEL-7404(B), U87MG(C), A549(D), HCT116(E), HT-29(F) and DU145(G) in vitro.

[0042] Fig. 9The figure shows the inhibitory effect of oncolytic vaccinia virus oncoVV-STRIP1shRNA#3 on U87MG mouse transplanted tumors in vivo, with PBS and oncoVV-GM-CSF as controls.

[0043] Fig.10 The effect of oncolytic vaccinia virus oncoVV-STRIP1shRNA#1 and oncoVV-STRIP1shRNA#3 on the survival time of U87MG tumor-bearing mice, with PBS and oncoVV-GM-CSF as controls. DETAILED DESCRIPTION

[0044] The following examples and experimental examples further illustrate the present invention and should not be construed as limiting the present invention. The examples do not include a detailed description of conventional methods, such as PCR methods, methods for constructing vectors and plasmids, methods for inserting protein-encoding genes into such vectors and plasmids, or methods for introducing plasmids into host cells. Such methods are well known to those skilled in the art and are described in many publications, including Sambrook, J., Fritsch, E. F. and Maniais, T. (1989) Molecular Cloning: A Laboratory Manual, 2 nd edition, Cold spring Harbor Laboratory Press.

[0045] Unless otherwise specified, percentages and parts are calculated by weight. Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention, and the preferred implementation methods and materials described in the specific implementation methods are for demonstration purposes only.

[0046] Example 1: siRNA interference of STRIP1 and STRIP2 leads to a significant decrease in the level of antiviral factors in malignant glioblastoma U87MG cells

[0047] STRIP1 or STRIP2 siRNA (purchased from Santa Cruz Biotechnology) was transfected into glioma cells U87MG, and non-specific RNA (Santa Cruz Biotechnology) was used as a control. The cell transfection process was as follows:

[0048] Follow the instructions in QIAGEN's Attractene Transfection Reagent Handbook:

[0049] (1) Before transfection, 3 × 10 4 500 μL of DMEM medium containing 1% double antibody and 10% fetal bovine serum was added to each well and cultured in a 37°C, 5% CO2 incubator.

[0050] (2) After the cells have attached to the wall (usually takes 2 to 3 hours, but may vary depending on the cell type), transfection is performed by adding an appropriate amount of RNA into a 0.5 mL centrifuge tube according to the siRNA instructions.

[0051] (3) Add 1.5 μL of transfection reagent to the centrifuge tube above, and then add serum-free and dual antibody-free culture medium to a final volume of 60 μL. Vortex on a vortex oscillator for 10 seconds to mix. Incubate at room temperature for 10 to 15 minutes.

[0052] (4) Use a pipette to gently aspirate the original cell culture medium in each well and add 500 μL of fresh cell culture medium containing 10% fetal bovine serum and 1% double antibody.

[0053] (5) Add the incubated transfection solution to the cells and culture them in a 37°C, 5% CO2 incubator. Change the medium after 6 to 18 hours.

[0054] Reverse transcription-PCR was used to detect the transcription levels of the antiviral factors Interferon-induced protein withtetratricopeptide repeats 1 (IFIT1), DExH-Box Helicase 58 (DHX58) and Interferon-stimulated gene 15 (ISG15) in the above cells, with GAPDH as the internal reference.

[0055] The experimental results are as follows Figure 1 As shown: siRNA interference of STRIP1 resulted in a significant decrease in the transcription levels of IFIH1, DHX58 and ISG15, and siRNA interference of STRIP2 resulted in a significant decrease in the transcription levels of DHX58 and ISG15, indicating that the inhibition of STRIP1 and STRIP2 can reduce the antiviral ability of tumor cells.

[0056] Example 2: SHRNA interference of STRIP1 down-regulates the expression level of antiviral factor IFI16 in liver cancer cell SMMC-7721

[0057] The STRIP1 shRNA interference plasmid was transfected into SMMC-7721 liver cancer cells to establish a stable expression cell line. A non-specific RNA plasmid was used as a control to establish a control cell line. The plasmid transfection method was the same as that in Example 1. The transfected cells were screened with puromycin to establish a stable transfected cell line. The cell screening method was as follows:

[0058] (1) Before screening, different concentration gradients of puromycin were added to the cells to be screened.

[0059] (2) Generally, after 48 hours, observe at which concentration gradient of puromycin the cell survival rate is zero, and then use this concentration of puromycin to screen the stable transfected cells.

[0060] (3) Transfect the cells to be screened and observe the transfection rate of the cells after 24 to 48 hours (the target plasmid used in this experiment has green fluorescence, and the transfection rate can be determined based on the amount of green fluorescence). When the transfection rate reaches about 50%, add the above-mentioned concentration of puromycin to the cells for cell screening.

[0061] (4) It is observed that all cells that are not transfected with the target plasmid are dead, that is, all surviving cells are cells with green fluorescence, and the cells are maintained with the selected concentration of puromycin until all surviving cells are cells transfected with the target plasmid.

[0062] Western blot was used to detect the expression levels of STRIP1 and IFI16 in the two cell lines, with actin as an internal reference.

[0063] The Western blot method is as follows:

[0064] (1) Preparation of protein samples

[0065] 3×10 5 BEL-7404 hepatoma cells with 100 cells were plated in a 6-well plate. After culturing overnight, 20MOI and 50MOI of Ad-EGFP and Ad-CTTNBP2NL were added to each well to infect the cells, and an equal volume of PBS was added to the cells as a control. After 48 hours, the supernatant and cells still attached to the wall were collected, centrifuged at 900 rpm for 3 min, the supernatant was discarded, 100 μL of SDS lysis buffer with PMSF (final concentration of 100 μg / mL) was added, the plate was placed on ice for 15 min, and centrifuged at 12000 rpm for 10 min. The supernatant was collected for protein concentration determination and stored at -20°C.

[0066] (2) Protein quantification (refer to the BCA protein quantification kit colorimetric method)

[0067] Add 20 μL of protein standard or protein sample to a 96-well plate, add 100 μL of BCA working reagent to each well, shake gently for 30 seconds, cover the 96-well plate with adhesive paper, and incubate at 37°C for 30 minutes. Take out the 96-well plate and cool to room temperature. Detect the OD reading at 562 nm on the microplate reader. Make a standard curve and calculate the protein sample concentration based on the standard curve.

[0068] (3) Protein sample pretreatment

[0069] Before electrophoresis, the sample loading amount and volume need to be calculated, and 1× SDS Loading Buffer is added to the protein sample. The sample is then boiled at 95°C in a metal bath for 5 minutes.

[0070] (4) Preparation of SDS polyacrylamide gel

[0071] Prepare the corresponding concentration of separation gel according to the molecular weight to be tested, align the two glass plates, install them into the sealing silicone frame, use ddH2O to check whether there is leakage, prepare 12% separation gel and 5% concentrated gel according to the following formula, and add TEMED before filling the gel. Pour out the ddH2O for leak detection and add the prepared separation gel, and slowly add anhydrous ethanol on the gel to make the gel agglutinate better. After about 40 minutes of separation gel agglutination, discard the anhydrous ethanol and add the prepared 5% concentrated gel, insert a clean 10-hole 1.5mm comb.

[0072] (5) SDS polyacrylamide gel loading and electrophoresis

[0073] After the gel is solidified, clamp the glass plate into the electrophoresis instrument, add electrophoresis buffer, gently pull out the comb vertically upwards, and add the prepared protein samples to each well in turn. After the loading is completed, connect the positive and negative electrodes, close the lid, and run the concentrated gel at 80V for about 30 minutes, until the sample reaches the junction of the concentrated gel and the separation gel, then change to 120V for about 1 hour.

[0074] (6) Transfer

[0075] When the blue Loading reaches the bottom of the gel, the electrophoresis is complete, turn off the power, remove the glass plate and use a scraper to gently pry between the two plates to separate the glass plate and the gel, and use the semi-dry transfer method to transfer the protein in the gel to the membrane. Soak the filter paper and sponge in the pre-cooled electrotransfer solution, soak the membrane of the appropriate size in methanol for 1 minute to activate it, and then soak it in the electrotransfer solution. With the white side of the clip at the bottom, lay the sponge, two filter papers, methanol-activated membrane, protein gel, two filter papers, and sponge in sequence. Pay attention to placing the membrane on the positive side and do not allow bubbles to appear. If there are bubbles between the membrane and the gel, you can drop a little electrotransfer solution to drive away the bubbles. Be gentle and do not drag the membrane and protein gel. Make sure it is completely laid out and there are no bubbles, then you can clamp the clip and put it in the electrotransfer tank. Fill it with pre-cooled electrotransfer solution and cover the lid. Place the electrotransfer tank in ice to facilitate cooling. Turn on the power, 100V, and transfer the membrane for 2 hours.

[0076] (7) Closed

[0077] Blocking allows the antibody to bind to specific proteins alone. Common blocking solutions in the laboratory are 5% BSA or skim milk powder, both of which are dissolved in TBST. We use 5% skim milk powder. After the transfer is completed, take out the membrane and soak it in the prepared blocking solution, place it on a shaker and incubate it for 2 hours, or in a 4°C refrigerator overnight.

[0078] (8) Primary antibody incubation

[0079] Prepare the primary antibody to be incubated according to the appropriate dilution ratio. Generally, dilute 10 mL of primary antibody incubation solution with 5% BSA (dissolved in TBST) at a ratio of 1:4000, and place it in a clean antibody incubation box for later use. Take out the blocked membrane, rinse the excess blocking solution in TBST, and immerse the membrane in the primary antibody dilution solution. Be careful not to have bubbles, and incubate it in a refrigerator at 4°C overnight.

[0080] (9) Washing

[0081] Wash three times with TBST, 10 minutes each time, to remove the non-specific binding between the primary antibody and the antigen. If the washing is not thorough, the background of the scanning result will be high.

[0082] (10) Secondary antibody incubation

[0083] Select the corresponding secondary antibody according to the primary antibody, dilute it with TBST at a ratio of 1:5000, and incubate it on a shaker at room temperature for 2 hours.

[0084] (11) Washing

[0085] After the secondary antibody incubation is completed, the membrane can be recovered and washed 3 times with TBST, 10 minutes each time, so that the non-specific binding of the secondary antibody can be washed away. Insufficient washing in this step will also result in a high background in the membrane scanning results.

[0086] (12) Scanning of membrane

[0087] Mix the A and B developer solutions in a 1:1 ratio, prepare as much as you need to avoid waste, store in a dark place, add developer solution to the membrane, soak the membrane completely, and then expose and develop it in an ultra-sensitive chemiluminescence instrument. Then take a photo of the marker under white light, merge the two images, and analyze them by comparing the size of the marker band.

[0088] The experimental results are as follows Figure 2 As shown: shRNA interference of STRIP1 resulted in a significant decrease in the expression level of the antiviral factor IFI16 in SMMC-7721 cells. The results further indicated that inhibition of STRIP1 could reduce the antiviral ability of tumor cells.

[0089] Example 3: SHRNA interference of STRIP1 can inhibit the activation of interferon-stimulated response element ISRE in tumor cells caused by vaccinia virus infection

[0090] A plasmid for STRIP1 shRNA interference was constructed and transfected into U87MG cells to establish a stable expression cell line. A plasmid expressing non-specific RNA was used as a control and transfected into cells to establish a control cell line. Both cells were infected or not infected with vaccinia virus and transfected with ISRE-Luc reporter plasmid, and cell proteins were collected for reporter gene detection as follows:

[0091] U87MG cells with good growth status were plated in 24-well plates at 80,000 cells per well and 0.5 mL of fresh culture medium. After the cells adhered to the wall, the ISRE firefly luciferase reporter gene plasmid and the Renilla luciferase plasmid were co-transfected with the cells at a concentration of 500:1 (following the above cell transfection steps), where the firefly luciferase reporter gene plasmid was 400 ng per well. After 6-8 hours of transfection, the culture medium was aspirated and 0.5 mL of fresh culture medium was added to reduce the toxicity of the transfection reagent to the cells. Then, the cells were lysed in the culture plate. First, the cells were washed, the culture medium was carefully aspirated, and sufficient PBS was slowly added along the wall of the plate. The culture plate was gently shaken up and down several times, and then the PBS was aspirated as clean as possible. Then, 100 μL of 1× lysis buffer was added to each well, and the culture plate was placed on a gently shaking shaker to ensure that the lysis buffer could completely cover the monolayer of cells. After shaking at room temperature for 15 minutes, the samples were transferred to clean 1.5 mL centrifuge tubes. The sample was diluted appropriately and then measured using a chemiluminescence microplate reader. During the measurement, the substrates of firefly luciferin and Renilla luciferin were ensured to be in sufficient excess (the substrates were prepared and used immediately).

[0092] The experimental results are as follows Figure 3 The results showed that shRNA interference of STRIP1 significantly inhibited the activation of ISRE transcriptional activity by vaccinia virus, indicating that inhibition of STRIP1 can reduce the response level of tumor cells to vaccinia virus.

[0093] Example 4: SHRNA interference of STRIP1 can increase the expression of caspase 3 and caspase 8

[0094] U87MG cells stably expressing STRIP1 shRNA were lysed, and cells expressing nonspecific RNA were used as controls. Total proteins were collected and Western blot was used to detect caspase 3 and caspase 8 in the cells. The Western blot method was described above.

[0095] The results are as follows Figure 4It was shown that interference with STRIP1 increased the expression of caspase 3 and caspase 8, indicating that interference with STRIP1 helps to increase the sensitivity of tumor cells to apoptosis induction.

[0096] Example 5: STRIP1 shRNA interference significantly delays the growth of transplanted tumors of U87MG cell line in mice

[0097] This study detected the growth of transplanted tumors in nude mice using the U87MG / STRIP1shRNA cells and control cells constructed in Example 3. Animal experiments were conducted in strict accordance with the NIH laboratory animal guidelines. Four-week-old female BALB / c nude mice were selected and subcutaneously injected with the above tumor cells at the axilla of their forelimbs. Each mouse was injected with 1x 10 7 After cell injection, the tumor volume was measured regularly with a micrometer. The tumor volume (mm 3 )=(length x width 2 ) / 2.

[0098] The results are as follows Figure 5 It shows that STRIP1 shRNA interference significantly delayed the growth of U87MG cell subcutaneous transplanted tumors in nude mice, but after a period of latency, it eventually reached the level of control cells.

[0099] Example 6. Construction and identification of vaccinia virus oncoVV-STRIP1 shRNA expressing STRIP1 shRNA

[0100] 1. Construction of pCB-STRIP1shRNA recombinant plasmid

[0101] According to Figure 6 The pCB-STRIP1shRNA recombinant plasmid was constructed by using the plasmid map shown in the figure. The coding DNA sequence of the shRNA that specifically inhibits the expression of STRIP1 is shown in Table 1 below. Of course, the RNA sequence can also be used for the construction of the recombinant plasmid.

[0102] Table 1 Summary of DNA sequences encoding shRNAs that specifically inhibit STRIP1 expression

[0103]

[0104]

[0105] The coding DNA sequences 1, 2 and 3 of the STRIP1shRNA sequence shown in the above table were inserted into the pCB plasmid through the Bgl II and Xba I sites, respectively, to obtain pCB-STRIP1shRNA#1, pCB-STRIP1shRNA#2 and pCB-STRIP1shRNA#3 plasmids. The vTK-L and vTK-R regions in the pCB plasmid were homologously recombined with the thymidine kinase TK region of the wild-type virus to insert the foreign gene sequence into the TK region, and at the same time cause TK deletion. The replication of vaccinia virus depends on TK, and the TK level of tumor cells is much higher than that of normal cells. Therefore, the TK-deficient vaccinia virus has the characteristic of specific replication in tumor cells.

[0106] In addition, the plasmid also carries the xanthine-guaninephoshporibosyl transferase (gpt) gene as a screening gene. The gpt gene comes from Escherichia coli. When mycophenolic acid (MPA) is present, the virus or cell will die because MPA can block guanine synthesis, which prevents the virus or cell from synthesizing nucleic acid normally. In the presence of the gpt gene, the cell or virus can use hypoxanthine and xanthine to synthesize guanine through an alternative pathway, so that nucleic acid synthesis is not restricted. By adding mycophenolic acid, hypoxanthine and xanthine to the culture medium to eliminate the wild-type virus, the purified recombinant virus is obtained.

[0107] 2. Recombination of Western Reserve (WR) vaccinia virus and pCB-STRIP1shRNA#1, pCB-STRIP1shRNA#2 or pCB-STRIP1shRNA#3 plasmids

[0108] (1) In area 6cm 2 Inoculate an appropriate number of 293A cells into a culture dish, so that they can grow to 80-90% of the cells on the next day;

[0109] (2) Discard the culture medium and gently add 1 mL of Western Reserve (WR) vaccinia virus (0.05-0.1 MOI, diluted with culture medium containing 2% serum) along the side wall. Incubate in a 37°C, 5% CO2 incubator for 2-4 hours, shaking the medium approximately every 15 minutes to prevent local cell death.

[0110] (3) Cell transfection was performed according to the instructions of the kit (Effectene), and the steps are as follows:

[0111] Add 1 μg of pCB-STRIP1shRNA to 150 μL of buffer EC, then add 8 μL of Enhancebuffer, oscillate for 1 second, and let stand at room temperature for 5 minutes; add 25 μL of Effectene buffer to the above three mixtures respectively, invert and mix 5 times, oscillate for 10 seconds, let stand at room temperature for 5-10 minutes, then add 1 mL of fresh culture medium (which may contain serum and antibiotics) to the above mixtures respectively, and invert twice; at the same time, discard the culture medium in step 2, add 4 mL of 10% FBS fresh culture medium, and add the mixed transfection solution thereto; place the culture dish in a 37°C, 5% CO2 incubator for 6-18 hours, then aspirate and discard the culture medium, wash once with PBS, and add 5 mL of fresh culture medium to continue culturing.

[0112] (4) After the cells have completely become diseased, collect the virus solution in a biosafety cabinet, divide it into centrifuge tubes, label them, and freeze-thaw the centrifuge tubes three times at -80°C and 37°C to completely lyse the cells and release the virus. Centrifuge at 2000 rpm for 5 min to collect the supernatant and store it in a -80°C ultra-low temperature refrigerator for later use.

[0113] 3. Screening of recombinant viruses

[0114] (1) 293A cells in good growth condition were inoculated into a culture dish. The cell density could reach about 80%-90% the next day.

[0115] (2) Prepare three screening drugs: xanthine, hypoxanthine, and mycophenolic acid.

[0116] (3) Carefully add 500 μL of the previously packaged virus solution to each culture dish in (1) along the side wall and incubate in a 37°C, 5% CO2 incubator for 2-4 hours. After about 2-4 hours, discard the suspended virus solution and add 3 mL of fresh culture medium containing 7.5 μL (1×) mycophenolic acid, 75 μL (1×) xanthine, and 7.5 μL (1×) hypoxanthine.

[0117] (4) Observe the cell pathological changes every day. After about two or three days, collect all the pathological cell fluid in a biological safety cabinet, freeze and thaw repeatedly three times, and store in a -80℃ ultra-low temperature refrigerator for future use.

[0118] (5) The collected virus fluid was screened 3 to 4 times according to the above method.

[0119] 4. Virus plaque picking and identification

[0120] (1) Preparation of 5% low melting point glue: Weigh 0.25 g of low melting point glue and dissolve it in 5 mL of PBS. Sterilize it by high pressure at 121°C for 20 min and then store it in a refrigerator at 4°C for later use.

[0121] (2) Inoculate 293A cells in good condition into a six-well plate. The next day, when the cell density reaches about 90%, add the virus solution at 10 -4 ~10 -6 Perform a series of dilutions in a gradient manner, then discard the old culture medium in the six-well plate, add 1 mL of diluted virus solution to each well to allow the virus to adsorb, and culture in an incubator for 2 to 4 hours. Place the boiled low-melting point gel in a 40°C water bath to keep warm, then place it in an ultra-clean bench, add three times the volume of DMEM culture medium to make its final concentration 1.25%, then quickly mix with a pipette and quickly use a pipette to discard the suspended virus solution in the plate, carefully add 2 mL of culture solution containing 1.25% low-melting point gel along the side wall with a pipette, being careful not to blow up the cells, and then culture them in a cell culture incubator at 37.5% CO2.

[0122] (3) Observe the cell lesions under an inverted microscope every day. If isolated virus plaques appear, pick them out and place them in a 12-well plate with 293A cells in advance. Label them and culture them in a cell culture incubator at 37°C and 5% CO2. After they are fully lesions, collect the virus liquid in a 1.51 mL centrifuge tube in a safety cabinet and store them in a -80°C ultra-low temperature refrigerator for the next step of identification.

[0123] (4) Using the feature that the wild-type virus has a complete TK region while the recombinant virus does not, PCR identification was performed to obtain purified vaccinia virus oncoVV-STRIP1shRNA#1, oncoVV-STRIP1shRNA#2, and oncoVV-STRIP1shRNA#3.

[0124] Example 7: The replication level of oncolytic vaccinia virus oncoVV-STRIP1 shRNA in tumor cells is significantly higher than that of control virus

[0125] Hepatoma cell line BEL-7404, glioma cell line U87MG and SHG44 were cultured at 5×10 3 / well density was inoculated into a 96-well plate, 90 μL of cell culture medium was added to each well for overnight culture, and 5 MOI of oncoVV-STRIP1shRNA#2, oncoVV-STRIP1shRNA#3 or control virus oncoVV was added respectively, and more than 3 replicate wells were set for each time gradient. The cells and culture medium were collected together, and the replication efficiency of the virus in tumor cells was detected by TCID50 method (half tissue culture infection dose). The method is as follows:

[0126] (1) Cell plating: HEK-293A cells were plated in a 96-well plate, with 4000 cells per well.

[0127] (2) Preparation of virus dilution solution: dilute the virus sample in a sterile clean bench: dilute the purified virus to 10% with serum-free DMEM. -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 and 10 -10 And so on for several different gradients.

[0128] (3) Infecting virus samples: The diluted virus samples were sequentially infected in 96-well plates, and each concentration gradient was repeated for 8 replicates. 100 μL of virus solution was added to each well. The plates were placed in a 37°C, 5% CO2 incubator and cultured normally for 5-8 days.

[0129] (4) Calculation of results

[0130] Virus titer calculation formula: For 100 μL sample, titer T = 10 1+d(s-0 .5);

[0131] d = log10 dilution = 1 (for a 10-fold dilution);

[0132] s = sum of positive ratios (starting from the first 10-fold dilution);

[0133] Convert TCID50 / mL to PFU / mL using the following formula:

[0134] T=a×10 b TCID50 / mL = a × 10 b-0.7 PFU / mL;

[0135] Test results such as Figure 7 As shown: The replication level of oncoVV-STRIP1shRNA#3 in the above three tumor cells was significantly better than that of oncoVV-STRIP1shRNA#2 and the control virus oncoVV.

[0136] Example 8: MTT assay to detect the in vitro inhibitory effects of oncoVV-STRIP1shRNA#3 and oncoVV-STRIP1shRNA#2 on tumor cells

[0137] In this study, breast cancer cells MDA-MB-231, liver cancer cells BEL-7404, glioma cells U87MG, lung cancer cells A549, colorectal cancer cells HCT116 and HT-29, and prostate cancer cells DU145 were selected and cultured at 5×10 3The cells were inoculated into a 96-well plate at a density of 1:1 / well, 90 μL of cell culture medium was added to each well and cultured overnight. 2 MOI, 5 MOI or 10 MOI of virus were added respectively, and 6 replicate wells were set up. The experimental control group was cells without virus, and the blank group was culture medium without cells.

[0138] Culture at 37°C, 5% CO2, set two time gradients of 48h and 72h, add 20μL MTT solution (5mg / mL) to each well in the dark at the corresponding time point. Let stand in the incubator for 4h, remove the culture solution of each group, add 150μL dimethyl sulfoxide to each well, and shake on a shaker for 10min to fully dissolve the crystals. Measure the OD value on an enzyme-linked detector, with a detection wavelength of 490nm.

[0139] The cell viability was calculated based on the measured OD value using the formula:

[0140] Cell survival rate = (OD value of the treatment group - OD value of the zero-adjustment group) / (OD value of the control group - OD value of the zero-adjustment group) × 100%.

[0141] The analysis results are as follows Figure 8 As shown, oncoVV-STRIP1shRNA#3 and oncoVV-STRIP1shRNA#2 significantly inhibited the proliferation of tumor cells in vitro in a dose- and time-dependent manner.

[0142] Example 9: oncoVV-STRIP1 shRNA significantly eliminated U87MG mouse transplanted tumors

[0143] Subcutaneous xenografts were established in nude mice using glioma cells U87MG. OncoVV-GM-CSF, oncoVV-STRIP1shRNA#3 or an equal volume of PBS were intraperitoneally injected, and the tumor volume was measured regularly. OncoVV-GM-CSF is similar to the oncolytic vaccinia virus drug Pexa-Vec (formerly known as JX-594) that has entered clinical phase III. It was constructed based on literature reports (Parato, KA, CJ Breitbach, et al. 2012. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated incancers. Mol Ther 20(4):749-758.). The animal experimental methods are as follows:

[0144] All animal experiments in this study were carried out in strict accordance with the NIH experimental animal guidelines. Four-week-old female BALB / c nude mice were selected and injected with 1x 10 7 The U87MG cells were injected subcutaneously at the axilla of the forelimb. The growth of the tumor volume was observed every day after the injection of the cells and measured with a micrometer to calculate the tumor volume (mm 3 )=(length×width 2 ) / 2). When the tumors grew to a stable state, they were divided into 3 groups: PBS group, oncoVV-GM-CSF group and oncoVV-STRIP1shRNA#3 group, with 6-8 nude mice in each group. After group division, each nude mouse was intraperitoneally injected with 1x10 7 pfu of virus or an equal volume of PBS, and then the tumor volume was measured regularly.

[0145] The results are as follows Fig. 9 Shown: oncoVV-STRIP1 shRNA#3 significantly eliminated U87MG mouse xenograft tumors compared to PBS and oncoVV-GM-CSF controls.

[0146] Example 10: oncoVV-STRIP1 shRNA significantly prolongs the survival time of mice

[0147] Subcutaneous xenografts were established in nude mice using glioma cells U87MG. 1×10 7 pfu oncoVV-GM-CSF, oncoVV-STRIP1shRNA#1, oncoVV-STRIP1shRNA#3 or an equal volume of PBS, and the time of mouse death was recorded. The animal experiment method was the same as described in Example 9.

[0148] The results are as follows Fig.10 As shown: Compared with PBS, oncoVV-GM-CSF, oncoVV-STRIP1shRNA#1 and oncoVV-STRIP1shRNA#3 all significantly prolonged the survival time of tumor-bearing mice, but oncoVV-STRIP1shRNA#3 was significantly superior to oncoVV-STRIP1shRNA#1 and oncoVV-GM-CSF.

[0149] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application. Sequence Listing <110> Hangzhou Gongchu Biotechnology Co., Ltd. <120> Inhibitors of striatin-interacting proteins and their use in the preparation of anti-tumor drugs <130> Claim description <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 70 <212> RNA <213> Artificial sequence <400> 1 agaucuccgg gcucaagcac uuuaaguuga acucgaguuc aacuuaaagu gcuugagcuu 60 uuugucuaga 70 <210> 2 <211> 70 <212> RNA <213> Artificial sequence <400> 2 agaucuccgg cgaaagcauc aagacucuga acucgaguuc agagucuuga ugcuuucguu 60 uuugucuaga 70 <210> 3 <211> 70 <212> RNA <213> Artificial sequence <400> 3 agaucuccgg gcaucugcuu cagacuugau ucucgagaau caagucugaa gcagaugcuu 60 uuugucuaga 70 <210> 4 <211> 58 <212> DNA <213> Artificial sequence <400> 4 ccgggctcaa gcactttaag ttgaactcga gttcaactta aagtgcttga gctttttg 58 <210> 5 <211> 58 <212> DNA <213> Artificial sequence <400> 5 ccggcgaaag catcaagact ctgaactcga gttcagagtc ttgatgcttt cgtttttg 58 <210> 6 <211> 58 <212> DNA <213> Artificial sequence <400> 6 ccgggcatct gcttcagact tgattctcga gaatcaagtc tgaagcagat gctttttg 58

Claims

1. Use of recombinant vectors of striatin-interacting protein inhibitors in the preparation of anti-tumor drugs, It is characterized in that The tumor is breast cancer, liver cancer, glioma, lung cancer, gastrointestinal carcinoid or prostate cancer; the recombinant vector includes an expression vector and STRIP siRNA, STRIP shRNA or STRIP antisense nucleotide inserted into the expression vector, and the expression vector is vaccinia virus.

2. Use of the striatin-interacting protein inhibitor recombinant vector according to claim 1 in the preparation of anti-tumor drugs, It is characterized in that: The striatin-interacting protein inhibitor is a short hairpin RNA, and the sequence of the short hairpin RNA is shown in SEQ ID NO.1, SEQ ID NO.2 or SEQ ID NO.

3.

3. Use of the striatin-interacting protein inhibitor recombinant vector according to claim 2 in the preparation of anti-tumor drugs, Features: in, The striatin-interacting protein inhibitor recombinant vector is STRIP shRNA vaccinia virus.

4. The striatin-interacting protein inhibitor recombinant vector according to any one of claims 1 to 3, It is characterized in that The recombinant vector comprises an expression vector and a STRIP siRNA, a STRIP shRNA or a STRIP antisense nucleotide inserted into the expression vector.

5. The striatin-interacting protein inhibitor recombinant vector according to claim 4, Features: in, The expression vector is vaccinia virus, and the vaccinia virus is vaccinia virus Western Reserve strain, vaccinia virus Tiantan strain, vaccinia virus Wyeth strain, vaccinia virus Copenhagen strain, vaccinia virus Lister strain or vaccinia virus NYCBH strain.

6. An anti-tumor drug composition, It is characterized in that The anti-tumor pharmaceutical composition comprises an active component and a medically acceptable excipient, carrier or diluent, wherein the active component is the striatin-interacting protein inhibitor recombinant vector described in any one of claims 1 to 5.

Citation Information

Patent Citations

  • Method for diagnosing and treating renal cell carcinoma

    CN101278059A

  • Diagnostic methods for determining prognosis of non-small cell lung cancer

    CN102656458A